FDA approves Telix brain cancer imaging drug Pixclara
Sep 14, 12:34 AM
TLX
- The FDA has approved Telix Pharmaceuticals' imaging agent, Pixclara, designed for assessing glioma patients.
- Pixclara, also known as floretyrosine F 18, is intended to be used with positron emission tomography (PET) scans.
- This approval signifies an advancement in the evaluation process for individuals diagnosed with gliomas.
Recommendation Rating: Highly Recommended
The Food and Drug Administration has granted approval to Telix Pharmaceuticals for its imaging agent, Pixclara, which is specifically designed to assist in the assessment of patients diagnosed with glioma. This announcement was made by the company on Sunday.
Known scientifically as floretyrosine F 18, Pixclara is intended for use in conjunction with positron emission tomography (PET) scans to enhance the evaluation process for individuals with this type of brain tumor.